Yn dangos 346 i 360 o 1609 canlyniadau
Fitness To Practise Annual Report 2020-21
Our Fitness to practise report highlights key insights from the year, explains how we protect the public and shows how we help registrants meet our standards
Record keeping under pressure
The factors to consider in applying our standards during the COVID-19 pandemic
Reclassification of Gabapentin and Pregabalin
From midnight on 1st April 2019, gabapentin and pregabalin will be reclassified as Schedule 3 controlled drugs, under the Misuse of Drugs Regulations (2001), and Class C of the Misuse of Drugs Act (1971)
Insights and data
Data and statistics on our regulatory work, including information on fitness to practise, registration and education processes
Diversity Data Report 2021
This report presents the findings from our registrant survey held between December 2020 and March 2021